The Arena Group Holdings, Inc.
US ˙ NYSEAM ˙ US0400441095

Introduction

This page provides a comprehensive analysis of the known insider trading history of Mark E Strome. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders
Companies with Reported Insider Positions

The SEC filings indicate Mark E Strome has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ZIVO / ZIVO Bioscience, Inc. 10% Owner 398,683
US:AREN / The Arena Group Holdings, Inc. 890,620
US:BEAT / HeartBeam, Inc. 10% Owner 57,146
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Mark E Strome. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases AREN / The Arena Group Holdings, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AREN / The Arena Group Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2019-03-18 MVEN STROME MARK E 1,500,000.0000 33,000,000.0000 147 0.9500
2018-06-15 MVEN STROME MARK E 3,000,000.0000 66,000,000.0000
2018-05-02 MVEN STROME MARK E 4,200 1.6200 191 35.6400 6,804
2018-05-01 MVEN STROME MARK E 27,000 1.6200 1,227 35.6400 43,740
2018-05-01 MVEN STROME MARK E 7,000 1.6600 318 36.5200 11,620
2018-04-30 MVEN STROME MARK E 3,700 1.5700 168 34.5400 5,809
2018-04-30 MVEN STROME MARK E 1,000 1.6800 45 36.9600 1,680
2018-04-27 MVEN STROME MARK E 29,408 1.5300 1,337 33.6600 44,994
2018-04-26 MVEN STROME MARK E 14,600 1.4600 664 32.1200 21,316
2018-04-25 MVEN STROME MARK E 2,910 1.4300 132 31.4600 4,161
2018-04-25 MVEN STROME MARK E 5,687 1.4400 258 31.6800 8,189
2018-04-25 MVEN STROME MARK E 5,000 1.4200 227 31.2400 7,100
2018-03-30 MVEN STROME MARK E 500,000 2.5000 22,727 55.0000 1,250,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AREN / The Arena Group Holdings, Inc. Insider Trades
Insider Sales AREN / The Arena Group Holdings, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AREN / The Arena Group Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2024-11-15 AREN STROME MARK E 217,574 1.7100 217,574 1.7100 372,052 59 1.1500 -121,841 -32.75

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AREN / The Arena Group Holdings, Inc. Insider Trades
Insider Purchases BEAT / HeartBeam, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AREN / The Arena Group Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BEAT / HeartBeam, Inc. Insider Trades
Insider Sales BEAT / HeartBeam, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AREN / The Arena Group Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BEAT / HeartBeam, Inc. Insider Trades
Insider Purchases ZIVOW / ZIVO Bioscience, Inc. - Equity Warrant - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AREN / The Arena Group Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2024-12-26 ZIVO STROME MARK E 75,000 20.1900 75,000 20.1900 1,514,250 730
2024-08-27 ZIVO STROME MARK E 30,000 8.4400 30,000 8.4400 253,200
2021-06-02 ZIVO STROME MARK E 40,000 4.9900 6,667 29.9400 199,600
2018-05-23 OTCQB:ZIVO STROME MARK E 4,268,163 0.1000 4,268,163 0.1000 426,816
2018-05-11 OTCQB:ZIVO STROME MARK E 8,819,966 0.1000 8,819,966 0.1000 881,997

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ZIVOW / ZIVO Bioscience, Inc. - Equity Warrant Insider Trades
Insider Sales ZIVOW / ZIVO Bioscience, Inc. - Equity Warrant - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AREN / The Arena Group Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ZIVOW / ZIVO Bioscience, Inc. - Equity Warrant Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Mark E Strome as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change		 Share
Price		 Tran
Value		 Remaining
Value
2025-01-23 2024-08-27 5 ZIVO Zivo Bioscience, Inc.
Common Stock 		P - Purchase 30,000 398,683 8.14 8.44 253,200 3,364,885
2025-01-23 2024-11-15 5 AREN Arena Group Holdings, Inc.
Common Stock 		S - Sale -217,574 890,620 -19.63 1.71 -372,052 1,522,960
2025-01-21 2025-01-17 4 ZIVO Zivo Bioscience, Inc.
Common Stock 		J - Other 34,000 432,683 8.53 18.50 629,000 8,004,636
2024-12-31 2024-12-26 4 ZIVO Zivo Bioscience, Inc.
Common Stock 		P - Purchase 75,000 398,683 23.17 20.19 1,514,250 8,049,410
2024-06-20 2024-06-12 4 BEAT HeartBeam, Inc.
Common Stock 		A - Award 33,185 57,146 138.50
2024-01-30 3 AREN Arena Group Holdings, Inc.
Common Stock, par value $0.01 		186,123
2024-01-30 3 AREN Arena Group Holdings, Inc.
Common Stock, par value $0.01 		1,488,617
2024-01-30 3 AREN Arena Group Holdings, Inc.
Common Stock, par value $0.01 		1,108,194
2023-10-30 2021-06-02 4 ZIVO Zivo Bioscience, Inc.
Common Stock 		P - Purchase 40,000 203,601 24.45 4.99 199,600 1,015,969
2023-10-30 2021-06-02 4 ZIVO Zivo Bioscience, Inc.
Common Stock 		C - Conversion 326,286 326,286 8.00 2,610,288 2,610,288
2023-07-18 2023-07-13 4 BEAT HeartBeam, Inc.
Common Stock 		A - Award 23,961 23,961
2023-05-15 3 BEAT HeartBeam, Inc.
Common Stock 		3,150,000
2021-01-05 2020-12-31 4 MVEN theMaven, Inc.
12% Senior Secured Subordinated Convertible Debenture 		C - Conversion 0
2021-01-05 2020-12-31 4 MVEN theMaven, Inc.
12% Senior Secured Subordinated Convertible Debenture 		C - Conversion 0
2021-01-05 2020-12-31 4 MVEN theMaven, Inc.
12% Senior Secured Subordinated Convertible Debenture 		J - Other
2021-01-05 2020-12-31 4 MVEN theMaven, Inc.
Common Stock 		C - Conversion 1,055,930 9,291,198 12.82 0.33 348,457 3,066,095
2021-01-05 2020-12-31 4 MVEN theMaven, Inc.
Common Stock 		C - Conversion 3,750,000 8,235,268 83.61 0.40 1,500,000 3,294,107
2020-11-02 2020-10-29 4/A MVEN theMaven, Inc.
Series H Convertible Preferred Stock 		J - Other 1,650 6,400 34.74
2020-11-02 2020-08-14 4/A MVEN theMaven, Inc.
Series H Convertible Preferred Stock 		P - Purchase 1,650 8,050 25.78 1,212.12 1,999,998 9,757,566
2020-11-02 2020-10-29 4/A MVEN theMaven, Inc.
Series H Convertible Preferred Stock 		J - Other -412 8,050 -4.87
2020-11-02 2020-10-29 4/A MVEN theMaven, Inc.
Series H Convertible Preferred Stock 		J - Other -82 8,462 -0.97
2020-11-02 2020-08-20 4/A MVEN theMaven, Inc.
Series H Convertible Preferred Stock 		P - Purchase 412 8,545 5.07 1,212.12 500,000 10,357,565
2020-11-02 2020-08-19 4/A MVEN theMaven, Inc.
Series H Convertible Preferred Stock 		P - Purchase 82 8,132 1.02 1,212.12 100,000 9,857,566
2020-10-13 2020-10-08 4 OTCQB:ZIVO Zivo Bioscience, Inc.
Common Stock Purchase Warrant 		P - Purchase 1,500,000 1,500,000
2020-08-21 2020-08-20 4 MVEN theMaven, Inc.
Series H Convertible Preferred Stock 		P - Purchase 412 8,545 5.07 1,000.00 412,500 8,545,000
2020-08-21 2020-08-19 4 MVEN theMaven, Inc.
Series H Convertible Preferred Stock 		P - Purchase 82 8,132 1.02 1,000.00 82,500 8,132,500
2020-08-18 2020-08-14 4 MVEN theMaven, Inc.
Series H Convertible Preferred Stock 		P - Purchase 1,650 8,050 25.78 1,000.00 1,650,000 8,050,000
2019-08-29 2019-08-28 4 MVEN theMaven, Inc.
Series H Convertible Preferred Stock 		P - Purchase 600 6,400 10.34 1,666.67 1,000,002 10,666,688
2019-05-01 2019-04-29 4 MVEN theMaven, Inc.
Series H Convertible Preferred Stock 		P - Purchase 200 5,800 3.57 1,000.00 200,000 5,800,000
2019-03-20 2019-03-18 4 MVEN theMaven, Inc.
12% Senior Secured Subordinated Convertible Debenture 		P - Purchase 1 1,500,000.00 1,500,000
2018-10-24 2018-06-28 4 OTCQB:ZIVO Zivo Bioscience, Inc.
Convertible Debt 		P - Purchase 691,187.00
2018-10-24 2018-06-07 4 OTCQB:ZIVO Zivo Bioscience, Inc.
Common Stock Purchase Warrant 		P - Purchase 9,000,000 9,000,000
2018-10-24 2018-06-07 4 OTCQB:ZIVO Zivo Bioscience, Inc.
Common Stock Purchase Warrant 		P - Purchase 16,000,000 16,000,000
2018-10-24 2017-11-21 4 OTCQB:ZIVO Zivo Bioscience, Inc.
Common Stock Purchase Warrant 		P - Purchase 333,333 1,000,000 50.00
2018-10-24 2017-11-21 4 OTCQB:ZIVO Zivo Bioscience, Inc.
Common Stock Purchase Warrant 		P - Purchase 666,667 666,667
2018-10-04 2018-08-10 4 MVEN theMaven, Inc.
Series H Convertible Preferred Stock 		P - Purchase 1,000 5,600 21.74 1,000,000.00 1,000,000,000 5,600,000,000
2018-10-04 2018-08-10 4 MVEN theMaven, Inc.
Series H Convertible Preferred Stock 		P - Purchase 1,000 5,600 21.74 1,000,000.00 1,000,000,000 5,600,000,000
2018-10-04 2018-08-10 4 MVEN theMaven, Inc.
Series H Convertible Preferred Stock 		P - Purchase 3,600 3,600
2018-10-04 2018-08-10 4 MVEN theMaven, Inc.
10% Convertible Debenture 		C - Conversion 0
2018-10-04 2018-06-15 4 MVEN theMaven, Inc.
Warrant (right to buy) 		P - Purchase 1 1
2018-10-04 2018-06-15 4 MVEN theMaven, Inc.
10% Convertible Debenture 		P - Purchase 1 3,000,000.00 3,000,000
2018-10-04 2018-05-02 4 MVEN theMaven, Inc.
Common Stock 		P - Purchase 4,200 4,485,268 0.09 1.62 6,804 7,266,134
2018-10-04 2018-05-01 4 MVEN theMaven, Inc.
Common Stock 		P - Purchase 7,000 4,481,068 0.16 1.66 11,620 7,438,573
2018-10-04 2018-05-01 4 MVEN theMaven, Inc.
Common Stock 		P - Purchase 27,000 4,474,068 0.61 1.62 43,740 7,247,990
2018-10-04 2018-04-30 4 MVEN theMaven, Inc.
Common Stock 		P - Purchase 1,000 4,447,068 0.02 1.68 1,680 7,471,074
2018-10-04 2018-04-30 4 MVEN theMaven, Inc.
Common Stock 		P - Purchase 3,700 4,446,068 0.08 1.57 5,809 6,980,327
2018-10-04 2018-04-27 4 MVEN theMaven, Inc.
Common Stock 		P - Purchase 29,408 4,442,368 0.67 1.53 44,994 6,796,823
2018-10-04 2018-04-26 4 MVEN theMaven, Inc.
Common Stock 		P - Purchase 14,600 4,412,960 0.33 1.46 21,316 6,442,922
2018-10-04 2018-04-25 4 MVEN theMaven, Inc.
Common Stock 		P - Purchase 5,000 4,398,360 0.11 1.42 7,100 6,245,671
2018-10-04 2018-04-25 4 MVEN theMaven, Inc.
Common Stock 		P - Purchase 5,687 4,393,360 0.13 1.44 8,189 6,326,438
2018-10-04 2018-04-25 4 MVEN theMaven, Inc.
Common Stock 		P - Purchase 2,910 4,387,673 0.07 1.43 4,161 6,274,372
2018-10-04 2018-03-30 4 MVEN theMaven, Inc.
Common Stock 		P - Purchase 500,000 4,384,763 12.87 2.50 1,250,000 10,961,908
2018-06-26 3 MVEN theMaven, Inc.
Common Stock 		8,943,478
2018-06-26 3 MVEN theMaven, Inc.
Common Stock 		8,943,478
2018-06-26 3 MVEN theMaven, Inc.
Common Stock 		8,943,478
2018-05-25 2018-05-23 4 OTCQB:ZIVO Zivo Bioscience, Inc.
Common Stock 		P - Purchase 4,268,163 13,088,129 48.39 0.10 426,816 1,308,813
2018-05-25 2018-05-11 4 OTCQB:ZIVO Zivo Bioscience, Inc.
Common Stock 		P - Purchase 8,819,966 8,819,966 0.10 881,997 881,997
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)